Nicotine receptor partial agonists for smoking cessation

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Cahill, Kate ^a   Stead, Lindsay F ^a   Lancaster, Tim ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Alkaloids therapeutic use ; Azocines therapeutic use ; Benzazepines therapeutic use ; Nicotine antagonists inhibitors ; Nicotinic agonists *therapeutic use ; Quinolizines therapeutic use ; Quinoxalines therapeutic use

Indexed keywords

AMFEBUTAMONE; CYTISINE; NALTREXONE; NICOTINE; VARENICLINE; ALKALOID; AZOCINE DERIVATIVE; BENZAZEPINE DERIVATIVE; NICOTINIC AGENT; QUINOLIZINE DERIVATIVE; QUINOXALINE DERIVATIVE;

ABDOMINAL PAIN; ABNORMAL DREAMING; ACUTE APPENDICITIS; ACUTE CORONARY SYNDROME; ACUTE PSYCHOSIS; ACUTE PYELONEPHRITIS; AGITATION; ANGINA PECTORIS; ANGIONEUROTIC EDEMA; BACKACHE; BILE DUCT CANCER; BLOODY DIARRHEA; BRAIN CANCER; BREAST CANCER; CELLULITIS; CHOLECYSTITIS; CLINICAL TRIAL; CONSTIPATION; CONVULSION; COUNSELING; DEHYDRATION; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECTOPIC PREGNANCY; GASTROINTESTINAL HEMORRHAGE; GRAND MAL SEIZURE; GUNSHOT INJURY; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INSOMNIA; IRRITABILITY; KNEE INJURY; LEG PAIN; LUNG CANCER; MAINTENANCE THERAPY; MENTAL INSTABILITY; NAUSEA; NICOTINE REPLACEMENT THERAPY; PERITONITIS; PNEUMONIA; POSTOPERATIVE HEMORRHAGE; RECTUM CARCINOMA; RESTLESSNESS; REVIEW; SALIVARY GLAND TUMOR; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SMOKING; SMOKING CESSATION; STROKE; SUBCAPSULAR CATARACT; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SYNCOPE; SYSTEMATIC REVIEW; THORAX PAIN; UNSTABLE ANGINA PECTORIS; VERTIGO; ANTAGONISTS AND INHIBITORS; DRUG THERAPY; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALKALOIDS; AZOCINES; BENZAZEPINES; BUPROPION; HUMANS; NICOTINE; NICOTINIC AGONISTS; QUINOLIZINES; QUINOXALINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION; VARENICLINE;

EID: 55049140591     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006103.pub3     Document Type: Review

References (98)

1. Aubin 2008 {published data only} Aubin H-J, Bobak A, Britton JR, Oncken C, Billing CB, Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trial. Thorax 2008;1:1-8. [: clinicaltrials.gov: ID NCT00143325]
2. Gonzales 2006 {published data only} Gonzales D, Jorenby DE, Brandon T, Arteaga C, Lee TC. Delayed quitting, lapse recovery and long-term outcomes for quitters taking varenicline, bupropion and placebo. Society for Research on Nicotine and Tobacco Annual Meeting, Portland OR, Feb 27-March 1st. 2008.
3. * Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an a4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 2006;296(1):47-55. [: clinicaltrials.gov ID: NCT00141206]
4. Jackson KC, Nahoopii R, Said Q, Dirani R, Brixner D. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. Journal of Occupational and Environmental Medicine 2007;49(4):453- 60.
5. Nides M, Glover ED, Reus VI, Christen AG, Make BJ, Billing CB, et al. Varenicline versus bupropion sr or placebo for smoking cessation: a pooled analysis. American Journal of Health Behavior 2008;32(6):664-75.
6. West R, Baker CL, Cappelleri JC, Bushmakin AG. Effect of varenicline and bupropion on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. UK National Smoking Cessation Conference Proceedings, London, June 2007. 2007.
7. Jorenby 2006 {published data only} Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al.Efficacy of varenicline, an a4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation. JAMA 2006;296(1):56-63. [: clinicaltrials.gov ID NCT00143364]
8. Nakamura 2007 {published data only} Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clinical Therapeutics 2007;29(6):1040-56. [: clinicaltrials.gov ID: NCT00139750]
9. Nides 2006 {published data only} * Nides M, Oncken C, Gonzalez D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective a4b2 nicotinic receptor partial agonist. Archives of Internal Medicine 2006;166:1561-8. [: clinicaltrials.gov ID: NCT00150241]
10. Oncken C, Watsky E, Reeves K, Anziano R. Varenicline is efficacious and well tolerated in promoting smoking cessation: Results from a 7-week, randomized, placebo- and bupropion-controlled trial [POS1-047]. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic. 2005.
11. Oncken 2006 {published data only} * Oncken C, Gonzalez D, Nides M, Rennard S, Watsky E, Billing CB, et al.Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist varenicline, for smoking cessation. Archives of Internal Medicine 2006;166:1571-7. [: clinicaltrials.gov ID: NCT00139750]
12. Oncken C, Watsky E, Reeves K, Anziano R. Smoking cessation with varenicline, a selective nicotinic receptor partial agonist: results from a phase 2 study [POS1-046]. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic. 2005.
13. Scharfenberg 1971 {published data only} Benndorf S, . Kempe G, Scharfenberg G, Wendekamm R, Winkelvoss E. Results of smoking cessation treatment with cytisin (Tabex) [Ergebnisse der medikamentösen raucherentwöhnung mit cytisin (Tabex)]. Das Deutsche Gesundheitwesen 1968;23(44):2092-6.
14. Benndorf S, Scharfenberg G, Kempe G, Wendekamm R, Winkelvoss E. Smoking cessation treatment with cytisin (Tabex): half-yearly outcomes for former smokers abstinent at four weeks from beginning of treatment [Medikamentöse raucherentwöhnung mit cytisin (Tabex): ergebnisse der halbjahresbefragung bei den vier wochen nach kurbeginn abstinenten ehemaligen rauchern]. Das Deutsche Gesundheitwesen 1970;24:774-6.
15. Benndorf S, Scharfenberg G, Kempe G, Winkelvoss E, Wendekamm R. Further reports on a double blind trial of the Bulgarian cytisine compound Tabex on 1214 smokers wishing to quit and practical experience in conducting clinics for such smokers [Weitere mitteilungen über einen doppelten blindversuch mit dem cytisinhaltigen bulgarischen präparat Tabex an 1214 entwö hnungswilligen rauchern und praktische erfahrungen bei der durchfürung einer sprechstunde für entwöhnungswillige raucher]. Das Deutsche Gesundheitswesen 1969;24:1135-40.
16. * Scharfenberg G, Benndorf S, Kempe G. Cytisine (Tabex) as a treatment for smoking cessation [Cytisin (Tabex) als medikamentöse raucherentwöhnungshilfe]. Das Deutsche Gesundheitwesen 1971;26(10):463-5.
17. Tonstad 2006 {published data only} Knight CJ, Howard PA, Baker CL. An evaluation of the cost-effectiveness of an extended course of varenicline in preventing smokers who have quit from relapsing [PSM3]. Value in Health 2007; Vol. 10, issue 6:A472.
18. * Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296(1):64-71. [: clinicaltrials.gov ID: NCT00143286]
19. Tsai 2007 {published data only} Tsai S-T, Cho H-J, Cheng H-S, Kim C-H, Hsueh K-C, Billing CB, Williams KE. A randomized, placebo-controlled trial of varenicline, a selective a4b2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clinical Therapeutics 2007;29(6):1027-39. [: clinicaltrials.gov ID: NCT00141167]
20. Williams 2007 {published and unpublished data} Reeves K, Watsky E, Williams K, Azoulay S, Billing B, Gong J. The safety of varenicline taken for 52 weeks for smoking cessation [RPOS3-54]. Society for Research on Nicotine and Tobacco 12th Annual Conference Orlando Fla, USA 2006.
21. Spangler JG, Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J. Comment and reply: A double-blind study evaluating the long-termsafety of varenicline for smoking cessation. Current Medical Research and Opinion 2008;24(2):577-9.
22. * Williams KE, Reeves KR, Billing CB, Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Current Medical Research and Opinion 2007;23(4):793- 801. [: clinical trials.gov ID: 00143299]
23. Burstein 2006 {published data only} Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetis, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers. Journal of Clinical Pharmacology 2006;46:1234-40.
24. Chantix 2006 {published data only} Pfizer Inc. Chantix prescribing information. http://www.chantix.com/content/Prescribing_Information. jsp (accessed 10th February 2007) 2006.
25. Granatowicz 1976 {published data only} Granatowicz J. Smoking cessation through the use of cytisine and other therapy. World Smoking Health 1976;1:8-11.
26. Kempe 1967 {published data only} Bacvarov VI. Smoking cessation through medication: remarks on G. Scharfenberg, E Winkelvoss and S. benndorf, Munch Med Wschr. 109 (1967) 1687-1689. Munchener Medizinische Wochenschrift 1967;109(50):2663-5.
27. * Kempe G. Observation about the Bulgarian medicine for smoking withdrawl Tabex, produced by Pharmachim-Sofia. Savr Med 1967;18(4):355-6.
28. Maliszewski 1972 {published data only} Maliszewski L, Straczynski A. Therapeutic use of Tabex. Wiadomoscie Lekarskie 1972;25(24):2207-10.
29. Marakulin 1984 {published data only} Marakulin VS, Komarov VM, Chuprin VV. Treatment of nicotinism [in Russian]. Voenno-Meditsinskii Zhurnal 1984;1:55-8.
30. Metelitsa 1987 {published data only} Metelitsa VI. Pharmacological agents in controlling smoking. Biulleten Vsesoiuznogo Kardiologicheskogo Nuachnogo Tsentra AMN SSSR 1987;10(1):109-12.
31. Monova 2004 {unpublished data only} Monova A, Monova D, Petrov V. Peneva E, Todorova M, Petrova M. Final report on double blind, placebo controlled, randomized clinical study for evaluation of efficacy, safety and tolerability of Tabex in patients with chronic nicotinism (tabacism): TAB - SPH - 04014. Sopharma plc unpublished report 2004.
32. Ostrovskaia 1994 {published data only} Ostrovskaia TP. Results of clinical investigation of anti-nicotine drug patches. Meditsinskaia Tekhnika 1994;3:42-3.
33. Paun 1968 {published data only} * Paun D, Franze J. [Smoking cessation with cytisine 'Tabex' tablets] [German] [Raucherentwö hnung mit cytisinhaltigen "Tabex" tabletten]. Sonderduck aus das deutsche Gesundheitwesen 1968;23(44):2088-91.
34. Paun D, Franze Y. Tabex: registering and treatment of smokers with chronic bronchitis in the consultation against tobacco smoking - Berlin. Medico-Biologic Information 1970;3:15-9.
35. Pfizer 2006 {unpublished data only} Pfizer Inc. Flexible Dosing Trial. NDA 21-928 [reported in CDER 2006] 2006.
36. Schmidt 1974 {published data only} Schmidt F. [Medical support of nicotine withdrawal. Report on a double blind trial in over 5000 smokers (author's transl)] [German] [Medikamentose unterstutzung der raucherentwohnung: bericht uber versuche an uber 5000 rauchern im doppelblindversuch]. Munch Med Wachr 1974;116(11):557-64.
37. Stapleton 2008 {published data only} Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008;103(1):146-54.
38. Stoyanov 1972 {published data only} Stoyanov S, Yanachkova M. [On the therapeutic effectiveness and tolerability of Tabex] [Bulgarian]. Savremenna Medicina 1972;23(6):30-3.
39. Zatonski 2006 {unpublished data only} Zatonski W, Cedzynska M, Przewozniak K, Karpinska E, Lewandowska D, Pstrucha E, et al.An open label observational study of herbal cytisine (Tabex) as an aid to smoking cessation [POS1-058]. Society for Research on Nicotine and Tobacco 11th Annual Meeting, 20-23 March 2005; Prague, Czech Republic. 2005.
40. * Zatonski W, Cedzynska M, Tutka P, West R. An uncontrolled trial of cytisine (Tabex) for smoking cessation. Tobacco Control 2006.
41. NCT00155298 {unpublished data only} Pfizer, National Taiwan University Hospital. A 12-week, double-blind, placebo-controlled, multicenter study with varenicline tartrate 1mg bid for smoking cessation. www.controlled-trials.com/mRCT/trial/123367 (accessed 21/2/2006) ClinicalTrials.gov ID NCT00155298.
42. NCT00282984 {unpublished data only} Pfizer. A 12-week, double-blind, placebo-controlled, multicentre study with a 40 week follow up evaluating the safety and efficacy of varenicline tartrate 1mg bid for smoking cessation in subjects with cardiovascular disease. www.controlled-trials.com/ mRCT/trial/145133 (accessed 21/2/2006) ClinicalTrials.gov ID NCT00282984.
43. NCT00285012 {unpublished data only} Pfizer. A 12-week, randomized, double-blind, placebo-controlled, multicentre trial with 40-week follow-up evaluating the safety and efficacy of varenicline tartrate for smoking cessation in patients withmild-to-moderate chronic obstructive pulmonary disease. www.controlled-trials.com/mRCT/trial/144987 (accessed 21/2/2006) ClinicalTrials.gov ID NCT00285012.
44. NCT00301145 {unpublished data only} SRI International. Varenicline tartrate with telephone-based counseling and/or internet-based counseling in helping adults stop smoking. http://clinicaltrials.gov/ct2/show/ NCT00301145 2005.
45. NCT00371813 {unpublished data only} Pfizer. A prospective, randomized, double-blind, placebo-controlled, multi-center multinational study of efficacy and safety of varenicline tartrate for smoking cessation. www.controlled-trials.com/mRCT/trial/186949 (accessed 21/9/2006) 2006; Vol. ClinicalTrials.gov ID NCT00371813.
46. NCT00463918 {unpublished data only} Pfizer. A phase 1 study to evaluate the pharmacokinetics of multiple doses of varenicline in healthy adolescent smokers. http://clinicaltrials.gov/ct2/show/NCT00463918 (accessed 18th April 2008) 2007.
47. NCT00502216 {unpublished data only} National Institute on Alcohol Abuse and Alcoholism. Naltrexone and varenicline: weight gain and tolerability on cigarette smokers. http://clinicaltrials.gov/ct2/show/ NCTNCT00502216 (accessed 14th April 2008) 2008.
48. NCT00523445 {unpublished data only} Inje University. The effects of varenicline on cognitive function in patients with schizophrenia. http://clinicaltrials.gov/ct2/show/NCT00523445 (accessed 14th April 2008) 2008.
49. NCT00525837 {unpublished data only} Butler Hospital/Brown University. Study of mood effects (varenicline) in depressed outpatient smokers. http://clinicaltrials.gov/ct2/show/NCT00525837 (accessed 14th April 2008) 2008; Vol. ClinicalTrials.gov ID NCT00525837.
50. NCT00548470 {unpublished data only} Manhattan Psychiatric Center. Varenicline effects in schizophrenic smokers. http://clinicaltrials.gov/ ct2/show/NCT00548470 (accessed 14th April 2008) 2008.
51. NCT00554840 {unpublished data only} University of Maryland. Comparison of varenicline and placebo for smoking cessation in schizophrenia. http://clinicaltrials.gov/ct2/show/NCT00554840 2007.
52. NCT00587769 {unpublished data only} Mayo Clinic. Chantix and bupropion for smoking cessation. http://clinicaltrials.gov/ct2/show/ NCT00587769 (accessed 14th April 2008) 2008.
53. NCT00594204 {unpublished data only} Pfizer. A 12-week double-blind, randomized, placebo-controlled, multi-center study with follow up evaluating the efficacy and safety of varenicline tartrate 1mg bid for smoking cessation. http://clinicaltrials.gov/ct2/show/NCT00594204 (accessed 14th April 2008) 2008.
54. NCT00595868 {unpublished data only} Pfizer. Efficacy of varenicline in ambivalent smokers. http://clinicaltrials.gov/ct2/show/ NCT00595868 2007.
55. NCT00596882 {unpublished data only} University of Pennsylvania. Message priming and enrollment in, and response to, a smoking cessation program: a pilot study. http://clinicaltrials.gov/ct2/show/NCT00596882 2008.
56. NCT00621777 {unpublished data only} Massachusetts General Hospital. A study of varenicline for prevention of relapse to smoking in patients with schizophrenia. http://clinicaltrials.gov/ct2/show/NCT00621777 (accessed 14th April 2008) 2008.
57. NCT00644969 {unpublished data only} Pfizer. Smoking cessation study for patients with schizophrenia or schizoaffective disorder. http://clinicaltrials.gov/ct2/show/NCT00644969 2008.
58. TASC 2007 {unpublished data only} Zatonski W, West R, Cedzynska M, Stapleton J, Aveyard P. The effect of Tabex (cytosine) on successful attempts to stop smoking. Short title: Tabex Smoking Cessation Trial (TASC). http://www.controlledtrials.com/mrct/trial/256813/tabex 2007.
59. ASH 2006 Raw M, McNeill A, Arnott D. Varenicline: guidance for health professionals on a new prescription-only stop smoking medication. www.ash.org.uk/html/cessation/ASHVareniclineguidance.pdf (accessed November 2006) 2006.
60. Balfour 2006 Balfour D. Personal communication November 13th 2006.
61. Bekelman 2003 Bekelman JE, Li Y, Gross GP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289(4):454-465.
62. Benowitz 1999 Benowitz NL. Nicotine addiction. Primary Care 1999;26:611-31.
63. Bhandari 2004 BhandariM, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al.Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Association Journal 2004;170(4):477-80.
64. Coe 2005 Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J, et al.Varenicline: an alpha4beta2 nAChR nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry 2005;48:3474-7.
65. DOH 1998 Department of Health. Smoking kills; a white paper on tobacco. http://www.archive.officialdocuments.co.uk/document/cm41/4177/4177.htm (accessed 25/1/2006). London: The Stationery Office, 1998.
66. Etter 2006 Etter J-F. Cytisine for smoking cessation: a literature review and a meta-analysis. Archives of Internal Medicine 2006;166:1-7.
67. Etter 2007 Etter J-F, Lukas RJ, Benowitz NL, West R, Dresler CM. Cytisine for smoking cessation: a research agenda. Drug and Alcohol Dependence 2007;92(1-3):3-8.
68. Fagerström 2006 Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opinion on Investigational Drugs 2006;15(2): 107-16.
69. Fagerström 2008 Fagerström K, Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatric Disease and Treatment 2008;4(2):1-11.
70. FDA 2008 Food, Drug Administration. FDA issues Public Health Advisory on Chantix. http://www.fda.gov/bbs/topics/NEWS/2008/NEW01788.html (accessed 14th April 2008) 2008.
71. Fiore 2004 Fiore MC, Croyle RT, Curry SJ, Cutler CM, Davis RM, Gordon C, et al.Preventing 3 million deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. American Journal of Public Health 2004;94(2):205-10.
72. Foulds 2004 Foulds J, Burke M, Steinberg M, Williams JM, Ziedonis DM. Advances in pharmacotherapy for tobacco dependence. Expert Opinion on Emerging Drugs 2004;9(1):39-53.
73. Glover 2007 Glover ED, Rath JM. Varenicline: progress in smoking cessation treatment. Expert Opinion. Pharmacotherapy 2007;8(11): 1757-67.
74. Gonzales 2001 Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, et al.Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clinical Pharmacology and Therapeutics 2001;69:438-44.
75. Hays 2008 Hays JT, Ebbert JO, Sood A. Efficacy and safety of varenicline for smoking cessation. American Journal of Medicine 2008;121(4A):S32-42.
76. Higgins 2003 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;7414:557-60.
77. Higgins 2008 Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 [updated February 2008]. http://www.cochrane-handbook.org 2008.
78. Hogg 2006 Hogg RC, Bertrand D. Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors (in press). Biochemical Pharmacology 2006.
79. Hughes 2003 Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine & Tobacco Research 2003;5(1):13-25.
80. Hughes 2007 Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD000031.pub3]
81. Keating 2006 Keating GM, Siddiqui MAA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs 2006;20(11):945-60.
82. Kerr 2007 Kerr JL, Timpe EM, Karpinski JP. Varenicline: a novel nicotinic receptor partial agonist for smoking cessation. Journal of Pharmacy Technology 2007;23(1):23-9.
83. Kuehn 2008 Kuehn BM. FDAwarns of adverse events linked to smoking cessation drug and antiepileptics. JAMA 2008;299(10):1121-2.
84. Lam 2007 Lam S, Patel PN. Varenicline: a selective α4β2 nicotinic acetylcholine receptor partial agonist approved for smoking cessation. cardiology in Review 2007;15(3):154-61.
85. Lexchin 2003 Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-76.
86. Mihalak 2006 Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at a4β2 and a full agonist at a7 neuronal nicotinic receptors. Molecular Pharmacology 2006;70(3):801-5.
87. NICE 2007 National Institute for Health and Clinical Excellence. Varenicline for smoking cessation. http://www.nice.org.uk/nicemedia/pdf/ TA123Guidance.pdf (accessed 14th April 2008). London: National Institute for Health and Clinical Excellence, 2007.
88. Papke 1994 Papke RL, Heinemann SF. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta2 subunit. Molecular Pharmacology 1994;45:142-9.
89. Picciotto 1999 Picciotto MR, Zoli M, Changeux JP. Use of knockout mice to determine the molecular basis for the actions of nicotine. Nicotine & Tobacco Research 1999;1(Suppl 2):S121-5.
90. Reus 2007 Reus VI, Obach RS, Coe JW, Faessel H, Rollema H, Watsky E, Reeves K. Varenicline: a new treatment with efficacy in smoking cessation. Drugs Today (Barc) 2007;43(2):65-75.
91. Sands 2005 Sands SB, Brooks PR, Chambers LK, Coe JW, Liu Y, Rollema H, et al.A new therapy for smoking cessation: varenicline, a selective nicotinic receptor partial agonist [SYM10C]. Society for Research on Nicotine and Tobacco 11th Annual Meeting. 20-23 March 2005; Prague, Czech Republic. 2005:14.
92. Slater 2003 Slater YE, Houlihan LM, Maskell PD, Exley R, Bermudez I, Lukas RJ, et al.Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology 2003;44:503-15.
93. Stead 2003 Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: 10.1002/14651858.CD000124]
94. Stead 2008 Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000146.pub3]
95. Surgeon General 2004 US Surgeon General. The health consequences of smoking: a report of the Surgeon General. www.cdc.gov/tobacco/sgr/sgr_2004/ index.htm (accessed 25/1/2006) 2004.
96. West 2005 West R, Hajek P, Stead L, Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005;100:299-303.
97. Wu 2006 Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. http://www.biomedcentral.com/1471-2458/6/300 2006.
98. Cahill 2007 Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006103.pub2]